Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: answer (791), key (390), explanation (95), resolution (118), result (1000), clarification (65), mix (142)

Annual report 2021-2022

Description: 2021/22 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2021/22 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-2021-2022.pdf

Annual report 20-21

Description: 2020/21 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2020/21 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-20-21.pdf

Patent foramen ovale (PFO) clinic - patient information

Description: Patient information factsheet Patent foramen ovale (PFO) clinic This leaflet provides information about your
Url: /Media/UHS-website-2019/Patientinformation/Heartandlungs/Patent-foramen-ovale-PFO-clinic-1572-PIL.pdf

UHS AR 21-22 Quality Account

Description: QUALITY ACCOUNT 2021/22 Part 1: QStaUteAmeLnItToYn qAuaClitCy fOroUm NtheTchief executive 2021/22 1.1 Chief executive’s statement and welcome
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-21-22-Quality-Account.pdf

AmB-(TICE)-Carboplatin-Etoposide

Description: Chemotherapy Protocol GERM CELL Amb TICE (Part 2): Carboplatin – Etoposide phosphate Ambulatory Regimen This regimen is for AMBULATORY CARE pathway use only use only
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/AmB-TICE-Carboplatin-Etoposide.pdf

Talimogene laherparepvec (T-VEC)

Description: Chemotherapy Protocol SKIN CANCER Talimogene laherparepvec (T-VEC) Regimen • Skin – Talimogene laherparepvec (T-VEC) Indication • Talimogene laherpa
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Talimogene-laherparepvec-T-VEC.pdf

Annual-report-and-quality-account-2019-20

Description: ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Trust Annual
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

Papers Trust Board 6 June 2024

Description: Date Time Location Chair Apologies Agenda Trust Board – Open Session 06/06/2024 9:00 - 13:00 Conference Room, Heartbeat/M
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Papers-Trust-Board-6-June-2024.pdf

DVd_Twice weekly_Daratumumab-Bortezomib-Dexamethasone_Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (twice weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (t
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Twice-weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

Isatuximab VRD weekly

Description: Chemotherapy Protocol Myeloma Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20) Regimen Myeloma – Isa-VRD weekly Isa
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Isatuximab-VRD-weekly-Ver1.pdf

11 to 20 of 204

Previous 1 2 3 4 5 … Next